Q4 2024 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) reported record revenues of $701 million for 2024, reaching the high end of their guided range.
- The company has secured separate CMS coverage and product-specific reimbursement codes for both EXPAREL and iovera, enhancing patient access and streamlining the billing process.
- Pacira BioSciences Inc (PCRX) received RMAT designation from the FDA for PCRX-201, with compelling two-year data from a Phase 1 study.
- The company is focused on a 5x30 strategy, aiming to benefit over 3 million patients annually by 2030 and achieve double-digit CAGR in product revenues over the next five years.
- Pacira BioSciences Inc (PCRX) has a strong balance sheet with $485 million in cash and investments, supporting their strategic initiatives and growth plans.
- The adoption of the new reimbursement pathway for EXPAREL under the NOPAIN Act is expected to take time, with more meaningful uptake anticipated in the second half of the year.
- There is pressure on gross margins due to discounting associated with GPO partnerships, despite volume growth and price increases.
- Non-GAAP SG&A expenses increased significantly, driven by investments in commercial, medical, and market access organizations.
- The company faces potential challenges from generic competition, although they remain confident in their IP estate and ongoing innovation.
- Pacira BioSciences Inc (PCRX) anticipates increased R&D expenses due to clinical study costs and investments in new product development, which could impact short-term profitability.
Good day, and thank you for standing by. Welcome to the Pacira BioSciences fourth-quarter 2024 conference call. (Operator Instructions) Please note that today's conference is being recorded.
I would now like to turn the call over to Susan Mesco, Head of Investor Relations. Please go ahead.
Thank you, operator, and good afternoon, everyone. Welcome to today's conference call to discuss our fourth-quarter and full-year 2024 financial results. Joining me are Frank Lee, Chief Executive Officer; and Shawn Cross, Chief Financial Officer. Kristen Williams, Chief Administrative Officer; Tony Molloy, Chief Legal Officer; Jonathan Slonin, Chief Medical Officer; and Brendan Teehan, Chief Commercial Officer, are also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements subject to the Safe Harbor provisions of federal securities laws. Such statements represent our judgment as of today and may involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
